EP1833511A4 - Method of treating brain cancer - Google Patents

Method of treating brain cancer

Info

Publication number
EP1833511A4
EP1833511A4 EP06717342A EP06717342A EP1833511A4 EP 1833511 A4 EP1833511 A4 EP 1833511A4 EP 06717342 A EP06717342 A EP 06717342A EP 06717342 A EP06717342 A EP 06717342A EP 1833511 A4 EP1833511 A4 EP 1833511A4
Authority
EP
European Patent Office
Prior art keywords
brain cancer
treating brain
treating
cancer
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06717342A
Other languages
German (de)
French (fr)
Other versions
EP1833511A2 (en
Inventor
Sui Xiong Cai
Mark B Anderson
Adam Willardsen
Nilantha Sudath Sirisoma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
Cytovia Therapeutics LLC
Original Assignee
Myriad Genetics Inc
Cytovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc, Cytovia Inc filed Critical Myriad Genetics Inc
Publication of EP1833511A2 publication Critical patent/EP1833511A2/en
Publication of EP1833511A4 publication Critical patent/EP1833511A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP06717342A 2005-01-03 2006-01-03 Method of treating brain cancer Withdrawn EP1833511A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64126305P 2005-01-03 2005-01-03
PCT/US2006/000122 WO2006074187A2 (en) 2005-01-03 2006-01-03 Method of treating brain cancer

Publications (2)

Publication Number Publication Date
EP1833511A2 EP1833511A2 (en) 2007-09-19
EP1833511A4 true EP1833511A4 (en) 2011-01-19

Family

ID=36648123

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06717342A Withdrawn EP1833511A4 (en) 2005-01-03 2006-01-03 Method of treating brain cancer

Country Status (7)

Country Link
EP (1) EP1833511A4 (en)
JP (1) JP2008526776A (en)
KR (1) KR20070117547A (en)
CN (1) CN101287369A (en)
AU (1) AU2006204052A1 (en)
CA (1) CA2592971A1 (en)
WO (1) WO2006074187A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545711A1 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
KR20100016385A (en) * 2007-04-10 2010-02-12 미리어드 파마슈티칼스, 인코포레이티드 Method of treating brain cancer
AU2008236995A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Dosages and methods for the treatment of cancer
FR2932180B1 (en) * 2008-06-04 2012-08-10 Centre Nat Rech Scient DIHYDRO ISO CA-4 AND THE LIKE: CYTOTOXICALLY POWERFUL, INHIBITORS OF TUBULIN POLYMERIZATION
TWI658047B (en) 2011-03-15 2019-05-01 吉斯藥品公司 Isoxazolidine derivatives
CA2829982A1 (en) 2011-03-15 2012-09-20 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
FR3019819B1 (en) 2014-04-09 2018-03-23 Centre National De La Recherche Scientifique (Cnrs) CYTOTOXIC COMPOUNDS INHIBITING TUBULIN POLYMERIZATION
CA3056970A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
EP3781565A1 (en) 2018-04-18 2021-02-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
FR3080620B1 (en) * 2018-04-27 2021-11-12 Univ Paris Sud COMPOUNDS WITH TUBULIN POLYMERIZATION INHIBITOR ACTIVITY AND IMMUNOMODULATORY PROPERTIES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014716A1 (en) * 1991-02-20 1992-09-03 Pfizer Inc. 2,4-diaminoquinazolines derivatives for enhancing antitumor activity
WO2005003100A2 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2006014420A1 (en) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
WO2006074147A2 (en) * 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88507A (en) * 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them
CA2265630A1 (en) * 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
MXPA00011773A (en) * 1998-05-28 2002-06-04 Parker Hughes Inst Quinazolines for treating brain tumor.
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014716A1 (en) * 1991-02-20 1992-09-03 Pfizer Inc. 2,4-diaminoquinazolines derivatives for enhancing antitumor activity
WO2005003100A2 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2006014420A1 (en) * 2004-07-06 2006-02-09 Angion Biomedica Corporation Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
WO2006074147A2 (en) * 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ASSEFA, HAREGEWEIN ET AL: "3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors", JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN , 17(8), 475-493 CODEN: JCADEQ; ISSN: 0920-654X, 2003, XP002613543 *
RACHID, ZAKARIA ET AL: "The Combi-Targeting Concept: Chemical Dissection of the Dual Targeting Properties of a Series of "Combi-Triazenes"", JOURNAL OF MEDICINAL CHEMISTRY , 46(20), 4313-4321 CODEN: JMCMAR; ISSN: 0022-2623, 2003, XP002613544 *

Also Published As

Publication number Publication date
CA2592971A1 (en) 2006-07-13
CN101287369A (en) 2008-10-15
WO2006074187A3 (en) 2008-01-10
KR20070117547A (en) 2007-12-12
AU2006204052A1 (en) 2006-07-13
WO2006074187A2 (en) 2006-07-13
JP2008526776A (en) 2008-07-24
EP1833511A2 (en) 2007-09-19

Similar Documents

Publication Publication Date Title
ZA200800907B (en) Treatment of cancer
EP2044026A4 (en) Method of treatment of glioma brain tumour
EP2144504A4 (en) Method of treating brain cancer
EP1991230A4 (en) Methods of treating cancer
EP1885400A4 (en) Methods of treating brain tumors with antibodies
ZA200802064B (en) Method for the treatment of acne
EP1833511A4 (en) Method of treating brain cancer
EP1909854A4 (en) Method for treating cancer
IL188430A0 (en) Treatment of tumors
EP1755394A4 (en) Cancer treatment method
EP1906963A4 (en) Method of treating ischemia-reperfusion injury
IL183059A0 (en) Cancer treatment method
IL179323A0 (en) Cancer treatment method
IL199689A0 (en) Compounds and method for treatment of cancer
HK1164767A1 (en) Compounds and methods for the treatment of cancer
IL188728A0 (en) Methods of treating epileptogenesis
IL238394A0 (en) Cancer treatment method
EP2225226A4 (en) Compounds and method for treatment of cancer
IL179359A0 (en) Cancer treatment method
EP2088862A4 (en) Cancer treatment method
EP2068911A4 (en) Methods for treating cancer
EP1802617A4 (en) Cancer treatment method
GB0520067D0 (en) Treatment of cancer
IL226363A0 (en) Compounds and methods for the treatment of cancer
GB2424579B (en) Method of treating hair

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070629

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1102261

Country of ref document: HK

R17D Deferred search report published (corrected)

Effective date: 20080110

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/517 20060101ALI20080124BHEP

Ipc: A01N 43/54 20060101AFI20080124BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20101222

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20101213BHEP

Ipc: A61K 31/4706 20060101ALI20101213BHEP

Ipc: A61K 31/5377 20060101ALI20101213BHEP

Ipc: A61K 31/517 20060101ALI20101213BHEP

Ipc: A01N 43/54 20060101AFI20080124BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20101230

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1102261

Country of ref document: HK